CA3186295A1 — Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
Assigned to Baili Bio Chengdu Pharmaceutical Co Ltd · Expires 2021-12-16 · 4y expired
What this patent protects
A camptothecin drug having a high-stability hydrophilic connecting unit, and a conjugate or pharmaceutically acceptable salt thereof, and a preparation method therefor and an application thereof in the prevention or treatment of cancer. The conjugate can specifically bind to a re…
USPTO Abstract
A camptothecin drug having a high-stability hydrophilic connecting unit, and a conjugate or pharmaceutically acceptable salt thereof, and a preparation method therefor and an application thereof in the prevention or treatment of cancer. The conjugate can specifically bind to a receptor highly expressed in tumor cells. The camptothecin drug has good water solubility, stability and uniformity, and can be used for preventing or treating diseases such as tumors.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.